U.S. Department of Energy, Sunvapor and Oberon Fuels Aim to Unlock Zero-Emission Renewable Fuel Production with Test of Novel Solar Steam & Battery Technology
June 13, 2023 09:01 ET
|
Oberon Fuels
Demonstration project will replace natural gas with zero-emission solar energy for production of Oberon’s rDME® fuel SAN DIEGO, June 13, 2023 (GLOBE NEWSWIRE) -- The U.S. Department of Energy is...
DCC Energy and Oberon Fuels to Boost Renewable Dimethyl Ether Production to Reduce Emissions of European LPG Market
March 29, 2023 07:00 ET
|
Oberon Fuels
SAN DIEGO and DUBLIN, Ireland, March 29, 2023 (GLOBE NEWSWIRE) -- DCC plc, the leading international sales, marketing and support services group, has partnered with Oberon Fuels, the leading...
ONL Therapeutics Closes First Tranche of $15 Million Series C Financing to Advance Lead Compound into Phase 2 Clinical Trial
March 08, 2023 07:00 ET
|
ONL Therapeutics
ANN ARBOR, Mich., March 08, 2023 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal...
ONL Therapeutics to Present at the XXVth Biennial Meeting of the International Society for Eye Research
February 13, 2023 07:00 ET
|
ONL Therapeutics
ANN ARBOR, Mich., Feb. 13, 2023 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal...
ONL Therapeutics to Present at 2023 BIO CEO & Investor Conference
February 02, 2023 07:00 ET
|
ONL Therapeutics
ANN ARBOR, Mich., Feb. 02, 2023 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal...
ONL Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for ONL1204 Ophthalmic Solution
February 01, 2023 07:00 ET
|
ONL Therapeutics
ANN ARBOR, Mich., Feb. 01, 2023 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal...
ONL Therapeutics to Highlight New Data in Upcoming Scientific Presentations at the 46th Annual Macula Society Meeting and the XXVth Biennial Meeting of the International Society for Eye Research
January 26, 2023 07:00 ET
|
ONL Therapeutics
ANN ARBOR, Mich., Jan. 26, 2023 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal...
Durable Medical Equipment (DME) Market will Revenue to Cross US$ 282900 million in 2022 to 2028 Research by Business Opportunities, Top Companies report covers, Market-specific challenges, consumption by Regional data
October 17, 2022 08:39 ET
|
Proficient Market Insights
PUNE, Oct. 17, 2022 (GLOBE NEWSWIRE) -- "Durable Medical Equipment (DME) Market" | No. of pages: 87| research report focus on overall information that can help to take decisions on current market...
NeuroSigma Announces Receipt of Permanent HCPCS Codes from CMS for Monarch eTNS System
September 27, 2022 12:00 ET
|
NeuroSigma, Inc.
LOS ANGELES, Sept. 27, 2022 (GLOBE NEWSWIRE) -- NeuroSigma, Inc., a Los Angeles-based bioelectronics company, announced that the Centers for Medicare & Medicaid Services ("CMS") has confirmed...
ONL Therapeutics Appoints Sushanta Mallick as Chief Development Officer
February 09, 2022 07:00 ET
|
ONL Therapeutics
ANN ARBOR, Mich., Feb. 09, 2022 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal...